AP56A - Hepatitis B virus surface antigens and hybrid antigehs containing them. - Google Patents

Hepatitis B virus surface antigens and hybrid antigehs containing them. Download PDF

Info

Publication number: AP56A
Authority: AP; ARIPO
Prior art keywords: pro; gly; protein; ser; ala
Prior art date: 1987-01-30

Application number

APAP/P/1988/000078A

Other languages

English (en)

Other versions

AP8800078A0 (en

Inventor

Teresa Cazebon

Wilde Michael De

Nigel Harford

Original Assignee

Smithkline Biologicals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-30

Filing date

1988-01-25

Publication date

1989-09-26

1987-11-01 Publication of AP8800078A0 publication Critical patent/AP8800078A0/xx

1988-01-25 Application filed by Smithkline Biologicals S A filed Critical Smithkline Biologicals S A

1989-09-26 Application granted granted Critical

1989-09-26 Publication of AP56A publication Critical patent/AP56A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

APAP/P/1988/000078A 1987-01-30 1988-01-25 Hepatitis B virus surface antigens and hybrid antigehs containing them. AP56A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US932587A	1987-01-30	1987-01-30

Publications (2)

Publication Number	Publication Date
AP8800078A0 AP8800078A0 (en)	1987-11-01
AP56A true AP56A (en)	1989-09-26

Family

ID=21736956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1988/000078A AP56A (en)	1987-01-30	1988-01-25	Hepatitis B virus surface antigens and hybrid antigehs containing them.

Country Status (20)

Country	Link
EP (1)	EP0278940A3 (de)
JP (1)	JPS6463382A (de)
KR (1)	KR880009130A (de)
CN (1)	CN1031395A (de)
AP (1)	AP56A (de)
AU (1)	AU1093088A (de)
DD (3)	DD285612A5 (de)
DK (1)	DK43188A (de)
FI (1)	FI880428L (de)
HU (1)	HUT50876A (de)
IL (1)	IL85216A0 (de)
MA (1)	MA21169A1 (de)
NO (1)	NO880395L (de)
NZ (1)	NZ223297A (de)
OA (1)	OA08801A (de)
PT (1)	PT86640B (de)
SU (1)	SU1746887A3 (de)
TN (1)	TNSN88004A1 (de)
YU (1)	YU17488A (de)
ZA (1)	ZA88488B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL86832A (en)	1987-06-22	2002-09-12	Medeva Holdings Bv	A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
IL89991A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of hepatitis b pres2 protein in methylotrophic yeasts
EP0345792A3 (de) *	1988-06-10	1991-05-02	F. Hoffmann-La Roche Ag	HTLV-1/HIV-1-Fusionsproteine
FR2635532B1 (fr) *	1988-07-29	1992-05-22	Pasteur Institut	Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5130247A (en) *	1989-09-19	1992-07-14	Merck & Co., Inc.	Expression of fusion protein of HIV envelope and HBsAG
EP0421626A1 (de) *	1989-09-19	1991-04-10	Merck & Co. Inc.	Vakzin gegen AIDS und Hepatitis B
US5130248A (en) *	1989-09-19	1992-07-14	Merck & Co., Inc.	Expression of fusion protein of HIV envelope and HBsAg
EP0491077A1 (de) *	1990-12-19	1992-06-24	Medeva Holdings B.V.	Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
JP3954643B2 (ja) *	1991-11-16	2007-08-08	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
WO1993013120A1 (en) *	1991-12-23	1993-07-08	Chiron Corporation	Hbv amplifier probes for use in solution phase sandwich hybridization assays
US6297048B1 (en)	1992-02-04	2001-10-02	Chiron Corporation	Hepatitis therapeutics
US5928902A (en) *	1992-02-27	1999-07-27	Smithkline Beecham Biologicals (S.A.)	Hybrid protein between CS from plasmodium and HBsAg
US6169171B1 (en)	1992-02-27	2001-01-02	Smithkline Beecham Biologicals (S.A.)	Hybrid protein between CS from plasmodium and HBSAG
ES2287969T3 (es) *	1992-03-06	2007-12-16	Innogenetics N.V.	Peptidos de vih.
US6667387B1 (en)	1996-09-30	2003-12-23	N.V. Innogenetics S.A.	HCV core peptides
US6709828B1 (en)	1992-03-06	2004-03-23	N.V. Innogenetics S.A.	Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
WO1993020840A1 (en) *	1992-04-14	1993-10-28	British Bio-Technology Limited	Induction of ctl responses
JP3626996B2 (ja)	1992-05-23	2005-03-09	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
CN1063343C (zh) *	1993-04-27	2001-03-21	中国科学院上海生物化学研究所	氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en)	1994-10-05	2001-05-22	The General Hospital Corporation	Hepatitis C virus vaccine
RU2189254C2 (ru) *	1995-06-06	2002-09-20	Америкэн Хоум Продактс Корпорэйшн	Вакцины против вирусов гепатита
ES2301178T3 (es)	1996-04-05	2008-06-16	Novartis Vaccines & Diagnostic	Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
EP2298900A1 (de)	1996-09-17	2011-03-23	Novartis Vaccines and Diagnostics, Inc.	Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
GB9623233D0 (en)	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
ES2284287T3 (es)	1998-10-16	2007-11-01	Glaxosmithkline Biologicals S.A.	Sistemas adyuvantes y vacunas.
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) *	2004-12-30	2008-04-16	成都生物制品研究所	含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) *	2005-08-12	2014-08-27	上海贺普药业股份有限公司	乙型肝炎病毒表面l蛋白相关肽
WO2007106536A2 (en)	2006-03-14	2007-09-20	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
SI2097102T1 (sl)	2006-09-07	2012-09-28	Glaxosmithkline Biolog Sa	Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
KR100836745B1 (ko) *	2007-01-31	2008-06-10	(주)두비엘	Ｈｂｖ 백신 및 그의 제조 방법
CA2678404C (en)	2007-02-28	2019-03-19	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
US8877208B2 (en)	2008-05-23	2014-11-04	The Regents Of The University Of Michigan	Multivalent nanoemulsion vaccines
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
JP7048482B2 (ja)	2015-08-03	2022-04-05	アメリカ合衆国	Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用
CN119780431A (zh) *	2025-03-11	2025-04-08	泰州蕾灵百奥生物科技有限公司	一种用于检测猪流行性腹泻的试剂盒及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1984002922A1 (en) *	1983-01-28	1984-08-02	Univ New York	Protective peptide antigen
EP0191748A1 (de) *	1985-02-07	1986-08-20	Smithkline Beecham Corporation	Malaria-Impfstoff
EP0201416A1 (de) *	1985-05-02	1986-11-12	Institut Pasteur	Partikel mit immunogenen HBs-Antigen-Eigenschaften und mit einer mit dem HBs-Antigen-Epitopen nichtverwandten antigenischen Stelle, Vektoren und tierische Zellen für die Herstellung dieser kombinierten Impfstoffartikel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU584580B2 (en) *	1982-09-08	1989-06-01	Smith Kline - Rit	Hepatitis B virus vaccine
DE3585578D1 (de) *	1984-06-18	1992-04-16	Chiron Corp	Hepatitisoberflaechenantigenpartikelvakzin.
EP0401941A3 (de) *	1984-07-11	1991-04-17	Takeda Chemical Industries, Ltd.	Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung
GB8421282D0 (en) *	1984-08-22	1984-09-26	Connaught Lab	Multispecific antigenic proteins
EP0175261B1 (de) *	1984-09-12	1991-12-11	Chiron Corporation	Hybridpartikel-Immunogene
EP0180012A1 (de) *	1984-10-27	1986-05-07	Wolfram H. Prof. Dr. Gerlich	Immunogene Polypeptidsequenz des Hepatitis B-Virus
US4774175A (en) *	1985-03-01	1988-09-27	Centocor, Inc.	Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) *	1985-04-03	1987-07-28	Smith Kline Rit, S.A.	Process for the extraction and purification of proteins from culture media producing them
EP0225887B1 (de) *	1985-04-08	1994-06-08	Amgen Inc.	Verfahren und hybridpromotor zur steuerung der exogenen gentranskription
US4816564A (en) *	1986-01-31	1989-03-28	Merck & Co., Inc.	Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) *	1986-06-03	1992-11-24	Hajime Horii	Yeast promoter and process for preparing heterologous protein

1988
- 1988-01-25 ZA ZA88488A patent/ZA88488B/xx unknown
- 1988-01-25 AP APAP/P/1988/000078A patent/AP56A/en active
- 1988-01-25 EP EP88870008A patent/EP0278940A3/de not_active Withdrawn
- 1988-01-26 NZ NZ223297A patent/NZ223297A/en unknown
- 1988-01-26 IL IL85216A patent/IL85216A0/xx unknown
- 1988-01-26 SU SU884355055A patent/SU1746887A3/ru active
- 1988-01-27 OA OA59269A patent/OA08801A/xx unknown
- 1988-01-27 PT PT86640A patent/PT86640B/pt not_active IP Right Cessation
- 1988-01-28 DK DK043188A patent/DK43188A/da not_active Application Discontinuation
- 1988-01-28 AU AU10930/88A patent/AU1093088A/en not_active Abandoned
- 1988-01-29 HU HU88409A patent/HUT50876A/hu unknown
- 1988-01-29 DD DD88334296A patent/DD285612A5/de unknown
- 1988-01-29 YU YU00174/88A patent/YU17488A/xx unknown
- 1988-01-29 DD DD88334295A patent/DD285994A5/de not_active IP Right Cessation
- 1988-01-29 FI FI880428A patent/FI880428L/fi not_active IP Right Cessation
- 1988-01-29 NO NO880395A patent/NO880395L/no unknown
- 1988-01-29 DD DD88334294A patent/DD284899A5/de not_active IP Right Cessation
- 1988-01-29 JP JP63021137A patent/JPS6463382A/ja active Pending
- 1988-01-29 MA MA21406A patent/MA21169A1/fr unknown
- 1988-01-30 KR KR1019880000825A patent/KR880009130A/ko not_active Withdrawn
- 1988-01-30 CN CN88100483A patent/CN1031395A/zh active Pending
- 1988-02-03 TN TNTNSN88004A patent/TNSN88004A1/fr unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1984002922A1 (en) *	1983-01-28	1984-08-02	Univ New York	Protective peptide antigen
EP0191748A1 (de) *	1985-02-07	1986-08-20	Smithkline Beecham Corporation	Malaria-Impfstoff
EP0201416A1 (de) *	1985-05-02	1986-11-12	Institut Pasteur	Partikel mit immunogenen HBs-Antigen-Eigenschaften und mit einer mit dem HBs-Antigen-Epitopen nichtverwandten antigenischen Stelle, Vektoren und tierische Zellen für die Herstellung dieser kombinierten Impfstoffartikel

Also Published As

Publication number	Publication date
FI880428A7 (fi)	1988-07-31
DD284899A5 (de)	1990-11-28
DK43188A (da)	1988-07-31
FI880428A0 (fi)	1988-01-29
DD285994A5 (de)	1991-01-10
EP0278940A2 (de)	1988-08-17
MA21169A1 (fr)	1988-10-01
OA08801A (fr)	1989-03-31
AP8800078A0 (en)	1987-11-01
NZ223297A (en)	1991-06-25
TNSN88004A1 (fr)	1990-07-10
FI880428L (fi)	1988-09-13
PT86640A (pt)	1988-02-01
ZA88488B (en)	1988-10-26
NO880395D0 (no)	1988-01-29
JPS6463382A (en)	1989-03-09
SU1746887A3 (ru)	1992-07-07
IL85216A0 (en)	1988-07-31
CN1031395A (zh)	1989-03-01
YU17488A (en)	1991-02-28
DD285612A5 (de)	1990-12-19
PT86640B (pt)	1992-01-31
HUT50876A (en)	1990-03-28
NO880395L (no)	1988-08-01
DK43188D0 (da)	1988-01-28
AU1093088A (en)	1988-08-04
EP0278940A3 (de)	1988-12-07
KR880009130A (ko)	1988-09-14

Publication	Publication Date	Title
EP0278940A2 (de)	1988-08-17	Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
KR0181940B1 (ko)	1999-04-01	변형된 HBsAg 라아지 단백질
US6306625B1 (en)	2001-10-23	Method for obtaining expression of mixed polypeptide particles in yeast
US4722840A (en)	1988-02-02	Hybrid particle immunogens
Wu et al.	1989	Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella.
CA1263618A (en)	1989-12-05	Hybrid particle immunogens
DE3789399T2 (de)	1994-10-06	Herstellung von Vakkzinen gegen Hepatitis B-Virus.
HK1003032B (en)	1998-09-30	Novel antigens and methods for their preparation
IE903370A1 (en)	1991-04-10	Chimaeric hepadnavirus core antigen proteins
EP0522030A1 (de)	1993-01-13	Vakzin gegen hepatitis b.
CA1222707A (en)	1987-06-09	Preparation of hepatitis b virus vaccine
WO1987007896A1 (en)	1987-12-30	T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
Delpeyroux et al.	1990	Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles
US6103519A (en)	2000-08-15	Antigens and methods therefor
Núñez et al.	2001	Cloning, expression, and purification of histidine-tagged preS domains of hepatitis B virus
EP1256804B1 (de)	2012-09-26	Expression, Nachweis und therapeutische Verwendungen des HBcAg
KR960004264B1 (ko)	1996-03-30	B형 간염 표면항원, 이의 생성 진핵 세포 및 백신의 제조방법, 검정방법 및 진단용 키트
DD274052A5 (de)	1989-12-06	Verfahren zur Herstellung von Rekombinanten Hbv-, Hiv- oder Plasmodium-Oberflächenproteinen bzw. Hybridpartikeln
Yu et al.	1990	Expression of pre‐S2 region of hepatitis B surface antigen in Escherichia coli
PT503252E (pt)	2001-09-28	Proteinas recombinantes com a imuno-reactividade do antigene e do virus da hepatite b (hbeag) processo para a sua preparacao e sua utilizacao em testes imunologicos e vacinas